Peptonic Medical announces results of the first part of its phase 2b study

Stockholm March 10th, 2017
Peptonic Medical AB (publ) today announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel was investigated for the treatment of vaginal atrophy, were not met. However, further analyses of the study data show that the gel, both without and with the active ingredient (oxytocin), had a marked and statistically significant alleviating effect on the Most Bothersome Symptoms (MBS) after the twelve week treatment.

Read more »

PEPTONIC medical deltog på Aktiedagen 2017

Den 6 mars genomfördes Aktiedagen 2017 i Stockholm och Peptonics VD Johan Inborr fanns på plats för att presentera bolaget.

Video med Johan Inborrs presentation »

Analysguiden 2016-06-22

Stor uppsida men hög risk. Peptonics pågående fas IIb-studie fortlöper som planerat. Studieresultaten väntas vara på plats i december och är avgörande för bolaget liksom för aktien. Vid positiva resultat är uppsidan stor.

Ladda ner analysguiden »

Recruitment of study subjects to PEPTONIC medical’s phase 2b study off to a good start

PEPTONIC medical today announced that 57 study subjects have been randomised in to its phase 2b study since the start of the study six weeks ago.

More about the phase 2b study »

Peptonic deltog på Småbolagsdagen

Den 13 juni deltog Peptonic på Småbolagsdagen i Stockholm och VD Johan Inborr presenterade då bolaget för deltagarna. Du kan ta del av Johans presentation här:

Johan Inborr presenterar Peptonic »